Skip to main content

Off-label-Anwendung von Infliximab

Off-label use of infliximab

Der Hautarzt volume 64, pages 757–761 (2013)Cite this article

Zusammenfassung

Der Tumornekrosefektor α (TNF) ist ein proinflammatorisches Zytokin und ein zentraler Entzündungsfaktor. Etliche TNFα-Antagonisten werden therapeutisch eingesetzt, darunter Infliximab, ein chimärer monoklonaler Antikörper mit Anti-TNFα-Aktivität. Zahlreiche Studien haben gezeigt, dass TNFα-Antagonisten in der Behandlung von Psoriasis – besonders bei schweren resistenten Formen – und Arthritis wirksam sind. Ferner wurden einige Kasuistiken und Studien zu TNFα bei neuen dermatologischen Indikationen publiziert. Ziel des Übersichtsartikels ist es, neue Off-label-Anwendungen von Infliximab anhand veröffentlichter Daten zusammenzufassen.

Abstract

Tumor necrosis factor α (TNFα) is a pro-inflammatory cytokine and a key mediator of inflammation. Several TNFα antagonists have been used therapeutically. One of them, infliximab, is a chimeric monoclonal antibody with anti-TNFα activity. Numerous studies have shown TNFα antagonists to be effective in treating psoriasis—particularly severe resistant forms—and arthritis. Additionally, several case reports and studies showing the effects of TNFα on new dermatologic indications have been published. The intention of this review is to summarize the new off-label uses of infliximab according to published data.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Literatur

  1. Adişen E, Oztaş M, Gürer MA (2008) Treatment of idiopathic pyoderma gangrenosum with infliximab: induction dosing regimen or on-demand therapy? Dermatology 216(2):163–165

    Article  PubMed  Google Scholar 

  2. Adnot-Desanlis L, Antonicelli F, Tabary T et al (2013) Effectiveness of infliximab in pityriasis rubra pilaris is associated with pro-inflammatory cytokine inhibition. Dermatology 226(1):41–46

    Article  CAS  PubMed  Google Scholar 

  3. Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O (2012) Anti-tumor necrosis factor-α induced systemic lupus erythematosus. Open Rheumatol J 6:315−319

    Article  CAS  PubMed  Google Scholar 

  4. Alokaily F, Alsaleh S, Al-Balawi M, Al-Rashidi S (2010) Efficacy of infliximab on the acute attack of uveitis. Saudi Med J 31(1):82-85

    PubMed  Google Scholar 

  5. Aringer M, Houssiau F, Gordon C et al (2009) Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48(11):1451–1454

    Google Scholar 

  6. Atzeni F, Sarzi-Puttini P, Doria A et al (2005) Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun Rev 4(3):144–152

    Article  CAS  PubMed  Google Scholar 

  7. Barde C, Laffitte E, Campanelli A et al (2011) Intralesional infliximab in noninfectious cutaneous granulomas: three cases of necrobiosis lipoidica. Dermatology 222(3):212–226

    Article  CAS  PubMed  Google Scholar 

  8. Barth D, Harth W, Treudler R, Simon JC (2009) Successful treatment of pityriasis rubra pilaris (type 1) under combination of infliximab and methotrexate. J Dtsch Dermatol Ges 7(12):1071–1074

    PubMed  Google Scholar 

  9. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ et al (2006) Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55(4):505-9

    Article  CAS  PubMed  Google Scholar 

  10. Cemil BC, Atas H, Canpolat F et al (2013) Infliximab-induced discoid lupus erythematosus. Lupus 22(5):515–518

    Article  CAS  PubMed  Google Scholar 

  11. Chan WP, Lee HS (2012) Combination therapy with infliximab and methotrexate in recalcitrant mucocutaneous Behçet disease. Cutis 89(4):185–190

    PubMed  Google Scholar 

  12. Chen D, Wang XB, Zhou Y, Zhu XC (2013) Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int

  13. Couriel DR, Saliba R, Lima M de et al (2009) A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15(12):1555–1562

    Article  CAS  PubMed  Google Scholar 

  14. Diab M, Coloe JR, Magro C, Bechtel MA (2010) Treatment of recalcitrant generalized morphea with infliximab. Arch Dermatol 146(6):601–604

    Article  PubMed  Google Scholar 

  15. Díaz-Ley B, Guhl G, Fernández-Herrera J (2007) Off-label use of biologic agents in the treatment of dermatosis, part 1: infliximab and adalimumab. Actas Dermosifiliogr 98(10):657–678

    Article  PubMed  Google Scholar 

  16. Doherty CB, Rosen T (2008) Evidence-based therapy for cutaneous sarcoidosis. Drugs 68(10):1361-1383

    Article  CAS  PubMed  Google Scholar 

  17. García-Rabasco A, Alsina-Gibert M, Pau-Charles I, Iranzo P (2012) Infliximab therapy failure in two patients with pemphigus vulgaris. J Am Acad Dermatol 67(5):196–197

    Article  Google Scholar 

  18. Garcovich S, Di Giampetruzzi AR, Antonelli G et al (2010) Treatment of refractory adult-onset pityriasis rubra pilaris with TNF-alpha antagonists: a case series. J Eur Acad Dermatol Venereol 24(8):881–884

    Article  CAS  PubMed  Google Scholar 

  19. Grant A, Gonzalez T, Montgomery MO et al (2010) Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 62:205–217

    Article  CAS  PubMed  Google Scholar 

  20. Hertl MS, Haendle I, Schuler G, Hertl M (2005) Rapid improvement of recalcitrant disseminated granuloma annulare upon treatment with the tumour necrosis factor-alpha inhibitor, infliximab. Br J Dermatol 152(3):552–555

    Article  CAS  PubMed  Google Scholar 

  21. Hostettler KE, Studler U, Tamm M, Brutsche MH (2012) Long-term treatment with infliximab in patients with sarcoidosis. Respiration 83(3):218-24

    Article  CAS  PubMed  Google Scholar 

  22. Jacobi A, Shuler G, Hertl M (2005) Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 153(2):448–449

    Article  CAS  PubMed  Google Scholar 

  23. Kanemaru H, Makino T, Jinnin M et al (2013) Case of neuro-Behçet’s disease successfully maintained a remission using infliximab for 2 years. J Dermatol

  24. Kolde G, Muche JM, Schulze P et al (2003) Infliximab: a promising new treatment option for ulcerated necrobiosis lipoidica. Dermatology 206(2):180–181

    Article  PubMed  Google Scholar 

  25. Lu R, George SJ, Hsu S (2006) Pityriasis rubra pilaris: failure of combination treatment with acitretin and infliximab. Dermatol Online J 12(4):18

    PubMed  Google Scholar 

  26. Magro-Checa C, Salvatierra J, Rosales-Alexander JL et al (2013) Life-threatening vasculo-Behçet following discontinuation of infliximab after three years of complete remission. Clin Exp Rheumatol

  27. Mang R, Ruzicka T, Stege H (2004) Therapy for severe necrotizing vasculitis with infliximab. J Am Acad Dermatol 51(2):321–322

    Article  PubMed  Google Scholar 

  28. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP(2011)A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative 4-week study. Rheumatology (Oxf) 50(3):593-597

  29. Matzkies FG, Manger B, Schmitt-Haendle M et al (2003) Severe septicaemia in a patient with polychondritis and Sweet’s syndrome after initiation of treatment with infliximab. Ann Rheum Dis 62(1):81–82

    Article  CAS  PubMed  Google Scholar 

  30. Meyerle JH, Shorr A (2003) The use of infliximab in cutaneous sarcoidosis. J Drugs Dermatol 2(4):413–414

    PubMed  Google Scholar 

  31. Meziane L, Caudron A, Dhaille F et al (2012) Febrile ulceronecrotic Mucha-Habermann disease: treatment with infliximab and intravenous immunoglobulins and review of the literature. Dermatology 225(4):344–348

    Article  CAS  PubMed  Google Scholar 

  32. Mrowietz U, Reich K (2009) Ten years of infliximab: its role in dermatology. Eur J Pharmacol 623 (Suppl 1):S10–S16

    Article  CAS  PubMed  Google Scholar 

  33. Patriarca F, Sperotto A, Damiani D et al (2004) Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 89(11):1352–1359

    CAS  PubMed  Google Scholar 

  34. Roddy E, Courtney PA, Morris A (2002) Non-Hodgkin’s lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab. Rheumatology (Oxford) 41(10):1194–1195

    Google Scholar 

  35. Rott S, Mrowietz U (2007) The use of infliximab in dermatology. J Dtsch Dermatol Ges 5(8):655–660

    Article  PubMed  Google Scholar 

  36. Scott-Lang V, Tidman M, McKay D (2012) Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatr Dermatol (Epub ahead print)

  37. Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behc¸et’s disease—review and basis for recommendations. Rheumatology (Oxford) 46:736–741

    Google Scholar 

  38. Shirakawa M, Uramoto K, Harada FA (2011) Treatment of acne conglobata with infliximab. J Am Acad Dermatol 55(2):344-6

    Article  Google Scholar 

  39. Streit M, Beleznay Z, Braathen LR (2006) Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds. Int Wound J 3:171–179

    Article  PubMed  Google Scholar 

  40. Takayama K, Ishikawa S, Enoki T et al (2013) Successful treatment with infliximab for Behçet disease during pregnancy. Ocul Immunol Inflamm 21(4):321–323

    Article  CAS  PubMed  Google Scholar 

  41. Toker E, Kazokoğlu H, Acar N( 2002) High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet’s disease.Br J Ophthalmol 86(5):521-523

    Article  CAS  PubMed  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. M. Onder, C. Salavastru und K. Fritz geben an, dass kein Interessenkonflikt vorliegt. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Affiliations

  1. Hautärzte und Laserzentrum , Reduitstr. 13, 76829, Landau, Deutschland

    M. Onder & K. Fritz

  2. Universität“Carol Davila” Bukarest, Bukarest, Rumänien

    C. Salavastru & K. Fritz

  3. Universität Bern, Bern, Schweiz

    K. Fritz

  4. Universität Osnabrück, Osnabrück, Deutschland

    K. Fritz

  5. Medizinische Fakultät, Gazi Universität Ankara, Ankara, Türkei

    M. Onder

Authors
  1. M. Onder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Salavastru
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Fritz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Onder.

Zusatzmaterial online

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Onder, M., Salavastru, C. & Fritz, K. Off-label-Anwendung von Infliximab. Hautarzt 64, 757–761 (2013). https://doi.org/10.1007/s00105-013-2596-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-013-2596-z

Schlüsselwörter

  • Tumornekrosefaktor α
  • Antagonist
  • Monoklonaler Antikörper
  • Inflammation
  • Zytokin

Keywords

  • Tumor necrosis factor α
  • Antagonist
  • Monoclonal antibody
  • Inflammation
  • Cytokine